

Anti-Inflammatory Reliever (AIR) Therapy

BUDESONIDE + FORMOTEROL
Symbicort® DuoResp Spiromax®



Short-Acting Beta2 Agonists (SABA)

SALBUTAMOL **SalAir® Ventolin®**
TERBUTALINE **Bricanyl®**



Short-Acting Muscarinic Antagonists (SAMA)

IPRATROPIUM
Atrovent®



Combination SABA + SAMA

SALBUTAMOL + IPRATROPIUM
Duolin HFA®



Relievers

Inhaled Corticosteroids (ICS)

FLUTICASONE propionate
Flixotide®



BUDESONIDE
Pulmicort®



BECLOMETHASONE dipropionate
Beclazone® Qvar® (ultrafine particle)



Note: Beclazone® and Qvar® are not dose equivalent and are not interchangeable.

Preventers

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

BUDESONIDE + FORMOTEROL
Symbicort® DuoResp Spiromax® Vannair®



*Symbicort 400/12 and DuoResp Spiromax 400/12 only funded if no more than 2 doses per day

Note: Symbicort 100/6, 200/6 and DuoResp Spiromax 200/6 are currently approved for Anti-Inflammatory Reliever (AIR) therapy. Vannair 100/6 and 200/6 is approved for maintenance use, but its use in AIR therapy is an unapproved indication.

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

FLUTICASONE propionate + SALMETEROL
Seretide®



*100/50 and 250/50 accuhaler only funded if no more than 2 doses per day

FLUTICASONE furoate + VILANTEROL
Breo Ellipta®



Controller + Preventer

Long-Acting Beta2 Agonists (LABA)

SALMETEROL
Serevent®



FORMOTEROL (eformoterol)
Oxis®



INDACATEROL
Onbrez Breezhaler®



Long-Acting Muscarinic Antagonists (LAMA)

TIOTROPIUM
Spiriva®



UMECLIDINIUM
Incruse Ellipta®



GLYCOPYRRONIUM
Seebri Breezhaler®



Funded by endorsement: LAMA inhaler is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly (i.e. COPD documented as indication on prescription).
Not subsidised if patient is also receiving treatment with another subsidised LAMA.

Combination Long-Acting Muscarinic Antagonists (LAMA) + Long-Acting Beta2 Agonists (LABA)

TIOTROPIUM + OLODATEROL
Spolto Respimat®



UMECLIDINIUM + VILANTEROL
Anoro Ellipta®




GLYCOPYRRONIUM + INDACATEROL
Ultibro Breezhaler®




Funded via Special Authority: LAMA + LABA inhaler is subsidised only for patients who have been stabilised on a LAMA and the prescriber considers that the patient would receive additional benefit from switching to a combination product. Not subsidised if patient is also receiving treatment with a combination ICS and LABA.

Combination Inhaled Corticosteroids (ICS) + Long-Acting Muscarinic Antagonist (LAMA) + Long-Acting Beta2 Agonist (LABA)

FLUTICASONE furoate + UMECLIDINIUM + VILANTEROL
Trelegy Ellipta®



BUDESONIDE + GLYCOPYRRONIUM + FORMOTEROL
Breztri Aerosphere®



Funded via Special Authority: ICS + LAMA + LABA 'triple therapy' inhaler is subsidised only for patients with a diagnosis of COPD confirmed by spirometry, or spirometry has been attempted and technically acceptable results are not possible and the patient is currently on an ICS/LABA or a LAMA/LABA, and meets the following clinical criteria:

- Patient has a COPD Assessment Test (CAT) score greater than 10, or
- Patient has had 2 or more exacerbations in the previous 12 months, or
- Patient has had one exacerbation requiring hospitalisation in the previous 12 months, or
- Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months

or the patient is currently receiving multiple inhaler triple therapy (ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to starting multiple inhaler triple therapy.

Long-acting Symptom Controllers (for COPD)

Spacers are available free to those who need them on a Practitioners Supply Order (PSO). Contact Health New Zealand | Te Whatu Ora for an order form on 0800 855 066. Everyone should have an action plan. Find a range of management plans at cardiacandrespiratory.org.nz

✓ Funded ✗ Not funded ✗ Partially funded

✓ Funded by endorsement ✗ Funded by Special Authority

✓ Low carbon footprint! ✗ High carbon footprint!

Funding information updated as of 1 September 2026.

Visit www.pharmac.govt.nz

cardiacandrespiratory.org.nz